122 related articles for article (PubMed ID: 22460814)
1. Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.
Troxell ML; Brunner AL; Neff T; Warrick A; Beadling C; Montgomery K; Zhu S; Corless CL; West RB
Mod Pathol; 2012 Jul; 25(7):930-7. PubMed ID: 22460814
[TBL] [Abstract][Full Text] [Related]
2. Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
Ang DC; Warrick AL; Shilling A; Beadling C; Corless CL; Troxell ML
Mod Pathol; 2014 May; 27(5):740-50. PubMed ID: 24186142
[TBL] [Abstract][Full Text] [Related]
3. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
4. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL
Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations in in situ and invasive breast carcinomas.
Miron A; Varadi M; Carrasco D; Li H; Luongo L; Kim HJ; Park SY; Cho EY; Lewis G; Kehoe S; Iglehart JD; Dillon D; Allred DC; Macconaill L; Gelman R; Polyak K
Cancer Res; 2010 Jul; 70(14):5674-8. PubMed ID: 20551053
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations in columnar cell lesions of the breast.
Dabbs DJ; Carter G; Fudge M; Peng Y; Swalsky P; Finkelstein S
Mod Pathol; 2006 Mar; 19(3):344-9. PubMed ID: 16400324
[TBL] [Abstract][Full Text] [Related]
11. Frequent PIK3CA mutations in radial scars.
Wolters KL; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Diagn Mol Pathol; 2013 Dec; 22(4):210-4. PubMed ID: 24193002
[TBL] [Abstract][Full Text] [Related]
12. Initiating breast cancer by PIK3CA mutation.
Miller TW
Breast Cancer Res; 2012 Feb; 14(1):301. PubMed ID: 22315990
[TBL] [Abstract][Full Text] [Related]
13. Multiplexed imaging reveals heterogeneity of PI3K/MAPK network signaling in breast lesions of known PIK3CA genotype.
Jacob T; Gray JW; Troxell M; Vu TQ
Breast Cancer Res Treat; 2016 Oct; 159(3):575-83. PubMed ID: 27581127
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
[TBL] [Abstract][Full Text] [Related]
15. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
16. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
[TBL] [Abstract][Full Text] [Related]
17. Multiplex PCR analysis of apocrine lesions shows frequent PI3K-AKT pathway mutations in both benign and malignant apocrine breast tumors.
Kanomata N; Yamaguchi R; Kurebayashi J; Moriya T
Med Mol Morphol; 2020 Mar; 53(1):15-20. PubMed ID: 31139940
[TBL] [Abstract][Full Text] [Related]
18. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
19. Novel method for PIK3CA mutation analysis: locked nucleic acid--PCR sequencing.
Ang D; O'Gara R; Schilling A; Beadling C; Warrick A; Troxell ML; Corless CL
J Mol Diagn; 2013 May; 15(3):312-8. PubMed ID: 23541593
[TBL] [Abstract][Full Text] [Related]
20. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
